Anergis’ technology of Contiguous Overlapping Peptides derives from original patents filed jointly by the University of Lausanne (UNIL), the University Hospital of Lausanne (CHUV) and the Federal Polytechnic School of Lausanne (EPFL), based on innovative research performed by Prof. Spertini in his laboratory.

Anergis acquired the above patents from UNIL/CHUV/EPFL in 2005 and further develops its intellectual property portfolio by filing product-specific patents.

Composition-of-matter patents have been filed by Anergis for its product candidates AllerT, AllerR and AllerDM.


  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:

This website uses cookies to ensure you get the best experience on our website.